<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/5d92c314-7feb-4c02-bb30-1528bc2343ee/HTML"><dcterms:extent>26 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/94699ea7-0dde-4c93-89b4-344f45ce49aa/PDF"><dcterms:extent>450 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/17d38a35-2f85-4937-b28c-6265b17cc751/TEXT"><dcterms:extent>24 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-RDPMWM6U"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2012</dcterms:issued><dc:creator>Fürst, Jurij</dc:creator><dc:format xml:lang="sl">številka:6</dc:format><dc:format xml:lang="sl">letnik:81</dc:format><dc:format xml:lang="sl">str. 487-492</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:36099589</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-RDPMWM6U</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">drug</dc:subject><dc:subject xml:lang="sl">farmakologija</dc:subject><dc:subject xml:lang="sl">možgansko-žilne bolezni</dc:subject><dc:subject xml:lang="sl">preprečevanje</dc:subject><dc:subject xml:lang="sl">srčno-žilne bolezni</dc:subject><dc:subject xml:lang="sl">strategije</dc:subject><dc:subject xml:lang="sl">zdravila</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Preprečevanje bolezni z zdravili - prihranek ali strošek?| Prevention of diseases with drugs - savings or costs?|</dc:title><dc:description xml:lang="sl">The paper discusses three approaches to cardiovascular disease prevention from the economic point of view: national programs for risk reduction, antiplatelet therapy and strategies of lipid lowering therapy. The most cost effective approach for cardiovascular risk reduction is a combination of population-wide prevention and the high-risk program with population screening. The high-risk program without populationwide prevention aggravates socio-economic inequalities. Acetylsalicylic acid is the antiplatelet drug of choice for cardiovascular disease prevention. Alternative antiplatelet drugs are cost-effective only for secondary prevention; clopidogrel only in case of contraindications for acetylsalicylic acid and dipyridamole in combination with acetylsalicylic acid only in the first two years after a cerebrovascular event. The "treat-to-target" model of lipid lowering treatment is less cost effective than an alternative approach to treating the whole population at risk with fixed doses of statins</dc:description><dc:description xml:lang="sl">Prispevek obravnava tri področja preprečevanja srčno-žilnih bolezni z ekonomskega vidika: nacionalne programe za zmanjševanje dejavnikov tveganja, antiagregacijska zdravila in strategije zdravljenja lipidov. Stroškovno najučinkovitejši pristop za zmanjšanje dejavnikov tveganja za srčno-žilne bolezni združuje populacijski program v kombinaciji s presejalnim. Izvajanje samo presejalnega programa je stroškovno manj učinkovito in vodi v večje razslojevanje družbe. Acetilsalicilna kislina je antiagregacijsko zdravilo izbire za preprečevanje aterosklerotičnih zapletov. Alternativna antiagregacijska zdravila so stroškovno učinkovita le v okviru sekundarne preventive klopidogrel za preprečevanje srčno-žilnih dogodkov, kadar je uporaba acetilsalicilne kisline kontraindicirana in kombinacija dipiridamola z acetilsalicilno kislino za preprečevanje ponovnih možgansko-žilnih zapletov prvi dve leti po prvem dogodku. Strategija zdravljenja lipidov v ciljne vrednosti ima verjetno slabšo stroškovno učinkovitost kot alternativna strategija zdravljenja vse populacije z določeno ravnjo tveganja za srčno-žilne bolezni z enotnimi odmerki statinov</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-RDPMWM6U"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-RDPMWM6U" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/94699ea7-0dde-4c93-89b4-344f45ce49aa/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-RDPMWM6U/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-RDPMWM6U" /></ore:Aggregation></rdf:RDF>